Genmab A/S (GMAB) vs Takeda Pharmaceutical (TAK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Genmab A/S (GMAB) has outperformed Takeda Pharmaceutical (TAK) over the past year, gaining 66.2% versus a gain of 52.2%. Over five years, TAK leads with a +60.9% price change compared with +29.1% for GMAB. Takeda Pharmaceutical is the larger company by market cap ($69.55 billion vs $31.20 billion), about 2.2 times the size.
On valuation, Genmab A/S trades at a lower forward P/E (32.0x vs 41.1x for Takeda Pharmaceutical). Takeda Pharmaceutical pays a dividend yielding 927.88%, while Genmab A/S does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GMAB | TAK |
|---|---|---|
| Share price | $50.60 | $21.77 |
| Market cap | $31.20B | $69.55B |
| 1-day change | -1.46% | +1.68% |
| YTD return | +64.29% | +39.64% |
| 1-year return | +66.17% | +52.24% |
| 5-year return | +29.15% | +60.90% |
| P/E ratio (TTM) | 43.25 | 311.00 |
| Forward P/E | 32.03 | 41.08 |
| EPS (TTM) | $1.17 | $0.07 |
| Dividend yield | 0.00% | 927.88% |
| Annual dividend | $0.00 | $202.00 |
| Revenue (latest FY) | $3.72B | — |
| Revenue growth (YoY) | +19.19% | — |
| Net income (latest FY) | $963.00M | — |
| Gross margin | 93.60% | — |
| Operating margin | 28.63% | — |
| Net margin | 25.89% | — |
| 52-week high | $59.97 | $22.07 |
| 52-week low | $23.62 | $14.16 |
| Distance from 52-week high | -15.62% | -1.36% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +28.48% | +12.68% |
| Average volume | 4.18M | 2.73M |
| Shares outstanding | 616.59M | 3.19B |
| Employees | 3,244 | 47,029 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Takeda Pharmaceutical is about 2.2 times larger than Genmab A/S by market value ($69.55B vs $31.20B).
- GMAB has outperformed TAK by 13.9 percentage points over the past year.
- Takeda Pharmaceutical trades at a higher earnings multiple (311.0x vs 43.2x trailing P/E).
- Takeda Pharmaceutical offers a meaningfully higher dividend yield (927.88% vs 0.00%).
About Genmab A/S
GMAB stock →Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy.
Health Care · Biotechnology: Pharmaceutical Preparations · 3,244 employees
About Takeda Pharmaceutical
TAK stock →Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience.
Health Care · Biotechnology: Pharmaceutical Preparations · 47,029 employees
GMAB vs TAK FAQ
Which is bigger, Genmab A/S or Takeda Pharmaceutical?
Takeda Pharmaceutical (TAK) is larger, with a market capitalization of $69.55B compared with $31.20B for Genmab A/S (GMAB).
Which stock has performed better over the past year, GMAB or TAK?
GMAB returned +66.17% over the past 12 months, compared with +52.24% for TAK (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, GMAB or TAK?
GMAB has the lower trailing P/E at 43.2, versus 311.0 for TAK. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Genmab A/S or Takeda Pharmaceutical?
Takeda Pharmaceutical pays a dividend yielding 927.88%, while Genmab A/S does not currently pay a regular dividend.
Are Genmab A/S and Takeda Pharmaceutical in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.